These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 12511531

  • 1. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Sato A, Hayashi K, Naruse M, Saruta T.
    Hypertension; 2003 Jan; 41(1):64-8. PubMed ID: 12511531
    [Abstract] [Full Text] [Related]

  • 2. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 4. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M.
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S, Takeuchi K, Mori T, Nako K, Ito S.
    Clin Exp Pharmacol Physiol; 2006 Jan; 33(5-6):477-9. PubMed ID: 16700881
    [Abstract] [Full Text] [Related]

  • 11. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, Araki H, Koya D, Kanasaki K, Oiso Y, Goto M, Nishiyama A, Kobori H, Imai E, Ando M, Matsuo S.
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [Abstract] [Full Text] [Related]

  • 12. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
    Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES.
    Endocr Pract; 2008 Nov; 14(8):985-92. PubMed ID: 19095597
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P.
    Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
    [Abstract] [Full Text] [Related]

  • 15. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ.
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [Abstract] [Full Text] [Related]

  • 16. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH.
    Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
    [Abstract] [Full Text] [Related]

  • 19. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
    Pitt B.
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):145-9. PubMed ID: 7786835
    [Abstract] [Full Text] [Related]

  • 20. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
    Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA.
    Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.